Gamaleya vaccine, financed by the state-run Russian Direct Investment Fund and backed by the military, last week completed a phase 1 trial involving Russian military personnel.
The institute hasn’t published results for the study, which involved about 40 people, but has begun the next stage of trials with a larger group.Gamaleya’s press office couldn’t be reached by phone Sunday.
Kremlin spokesman Dmitry Peskov didn’t respond to a text message asking whether President Vladimir Putin or others in his administration have had the shots.
A government spokesman couldn’t immediately comment.Russia has reported more than 750,000 cases of Covid-19, the fourth-largest total in the world, and Gamaleya’s program is on a faster track than many rivals.